DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
6th & Kipling St. (P.O. Box 25087)	6/10/2019-6/17/2019*			
Denver, CO 80225-0087 (303)236-3000 Fax:(303)236-3100	FEI NUMBER 3015414747			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
Vickilee K. Einhellig, CEO				
FIRM NAME	STREET ADDRESS			
Professional Pharmacy Services Inc dba	1749 Main St Unit D			
Good Day Pharmacy				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Longmont, CO 80501-7441	Non-Sterile Drug Manufacturer			

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1

You produced highly potent drugs without providing adequate containment, segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically,

Equipment, work surfaces, and utensils are used for the production of hormonal products as well as non-hormonal products. Inadequate cross-contamination precautions are established to protect drug products produced on these shared surfaces at the Good Day Longmont location as well as the Good Day Fort Collins location. You have failed to demonstrate that the use of the dish washer and manual cleaning operations (soap and water) are adequate to mitigate cross-contamination of products made on site. Non-dedicated equipment, utensils, and work surfaces include the (b) (4) hood, compounding counter adjacent to the hood, glass stirrers, metal spatulas, glass mortar and pestle, mesh sieves, (b) (4) capsule machines, unguator and mixing blades, ointment mill, troche mold, stir bars, and beakers.

a. On 6/4/2019 you made the following hormone containing prescription products and non-hormone containing prescription products with mixed use equipment, utensils, and workstations:

- Testosterone 10mg Mini Troche Rx (b) (6),^{(b) (4)}troches
- Progesterone 100mg IR Capsule Rx (b) (6),^{(b) (4)}:apsules
- BIEST (50:50) 0.1mg/gm(b) (4) 01.mg/gm cream Rx (b) (6),^{(b) (4)}
- Progesterone 75mg SR #1 75mg Capsule Rx (b) (6), ^{(b) (4)}capsules

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Zachary A Bogorad,	Investigator Zachary A Bogorad Beneficiator Series X Zachary A Bogorad Beneficiator Series X Zachary A Bogorad Beneficiator Series X Zachary A Bogorad Beneficiator Series X Zachary A Bogorad Beneficiator Series X Series Seri	DATE ISSUED 6/17/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 1 of 3 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
TRICT ADDRESS AND PHONE NUMBER DA		DATE(S) OF INSPECTION 6/10/2019-6/17/2019*		
Denver, CO 80225-0087	80225-0087			
(303)236-3000 Fax:(303)236-3100		3015414747		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED		I.		
Vickilee K. Einhellig, CEO FRM NAME	STREET ADDRESS			
		n St Unit D		
Good Day Pharmacy	TYPE ESTABLISHM			
Longmont, CO 80501-7441		ile Drug Manufacturer		
 Enrof 20mg/Prednisolone 5mg/Ursodiol 80mg/ml Oral Suspension Rx (b) (6), (b) (4) Prazosin 0.5mg Capsule Rx (b) (6), (b) (4) Ranitidine 30mg/mL Glycerin Oral Suspension Rx (b) (6) (b) (4) Clonidine 0.1mg/mL Oral Suspension Rx (b) (6) (b) (4) b. On 6/7/2019 you made the following hormone containing products and non-hormone containing products with mixed use equipment, utensils, and workstations ((b) (4) (b) (4) hood and compounding counter adjacent to the hood): 				
 Estradiol 5mg/gm Cream Rx (b) (6) (b) (4) Estradiol 15mg/gm Cream Rx (b) (6), (b) (4) Biest (80:20) 1.45mg/ Pregnenolone 65mg/ Progesterone 200mg/ Testosterone 0.65mg Sugar Free Troche Rx (b) (6) (b) (4) roches Testosterone 16% (160mg/gm) Cream Rx (b) (6), (b) (4) Gabapentin 50mg #3 Capsule Rx (b) (6), (b) (4) Omeprazole 2mg/ml Oral Suspension Rx (b) (6), (b) (4) 				
OBSERVATION 2				
You used a non-pharmaceutical grade component	in the formu	lation of a drug product.		
Specifically, your pharmacy makes non-sterile prescription drug products using purchased (b) (4) $^{(b) (4)}$ including (b) (4) and (b) (4)/grocery store brands. You have never reviewed or collected certificates of analysis or established specifications to ensure that $^{(b) (4)}$ used is appropriate for pharmaceutical production operations. Examples of products produced with purchased (b) (4) include:				
A. Triamcinolone 0.5% Oral Rinse liquid suspension, Rx (b) (6) made on 6/11/2019,(b) (4) BUD 6/25/2019				
SEE REVERSE OF THIS PAGE	gator	Zachary A Bogorad Investigator Signer By Zachary A. Bogorad -S Dalle Bigned 06-17-2019 09 57 06 X	DATE ISSUED 6/17/2019	
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE I	NSPECTIONAL O	DESERVATIONS	PAGE 2 of 3 PAGES	

	LTH AND HUMAN SERVICES UG ADMINISTRATION
District ADDRESS AND PHONE NUMBER 6th & Kipling St. (P.O. Box 25087) Denver, CO 80225-0087 (303)236-3000 Fax:(303)236-3100	DATE(5) OF INSPECTION 6/10/2019-6/17/2019* FEI NUMBER 3015414747
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Vickilee K. Einhellig, CEO	
FIRM NAME Professional Pharmacy Services Inc dba Good Day Pharmacy	street Address 1749 Main St Unit D
CITY, STATE, ZIP CODE, COUNTRY Longmont, CO 80501-7441	TYPE ESTABLISHMENT INSPECTED Non-Sterile Drug Manufacturer
B. Losartan 2.5mg/mL (Orasweet) suspension, Rx (b)	(6) made on 2/11/2019, (b) (4) _{BUD 3/11/2019}
*DATES OF INSPECTION 6/10/2019(Mon), 6/11/2019(Tue), 6/13/2019(Thu)), 6/17/2019(Mon)

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Zachary A Bogorad,	Investigator Zachary A Bogorad investigator State Signed 06-17-2019 (09 57 or X	DATE ISSUED 6/17/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 3 of 3 PAGES